Worldwide, ATRIAL FIBRILLATION is one of the most common causes of stroke. Researchers are now exploring the use of an investigational drug in patients with atrial fibrillation. Learn more on who can participate in the OCEANIC-AF study!
The OCEANIC-AF study is sponsored by Bayer.
Contact us for more information at 786-772-0510
